Everything below concerns melanotan-2. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-08. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
13 December – The 2025 New Zealand bravery awards are announced. 14 December: A large fire engulfs four hectares of gum trees and slash near a eucalyptus forest in Kerikeri. 20 firefighters, two helicopters and a digger are deployed. A large vegetation fire breaks out along State Highway 4 near Parikino in the Whanganui District. 400 Air New Zealand cabin crew affiliated with the E tū union call off a planned strike on 18 December after reaching an "in principle agreement" with their employer. 15 December: Armed police are deployed to guard several Jewish sites nationwide including Kadimah School in response to the 2025 Bondi Beach shooting, which occurred yesterday. Police recover the bodies of an Australian climber and a dual Canadian-New Zealand climber who went missing in Fiordland National Park over the weekend. A large vegetation fire breaks out near Waiinu Beach in South Taranaki, leading to the evacuation of local residents. 16 December: Justice Richard McIlraith of the Manukau District Court voids the results of the Papatoetoe subdivision of the Ōtara-Papatoetoe Local Board election during the 2025 Auckland Council election, citing significant electoral irregularities. The Otago Regional Council orders the Dunedin City Council to stop discharging wastewater into Surrey Street and the Caversham area by June 2027. The New Zealand Government reduces transport subsidies for elderly and disabled people from 75% to 65%. The New Zealand Government announces plans to create a new mega ministry called the Ministry for Cities, Environment, Regions and Transport (MCERT).
== Principle of chiral column chromatography == The chiral stationary phase, CSP, can interact differently with two enantiomers, by a process known as chiral recognition. Chiral recognition depends on various interactions such as hydrogen bonding, π-π interaction, dipole stacking, inclusion complexation, steric, hydrophobic and electrostatic interaction, charge-transfer interactions, ionic interactions etc, between the analyte and the CSP, to form in-situ transient-diastereomeric complexes. Most of the types of stationary phases can be classified as Pirkle type (Brush type), Protein-based, Cyclodextrins based, Polymer-based carbohydrates (polysaccharide-based CSPs), Macrocyclic antibiotic, Chiral crown ethers, imprinted polymers, etc.
== Enzyme diffusivity == The advent of single-molecule studies in the 2010s led to the observation that the movement of untethered enzymes increases with increasing substrate concentration and increasing reaction enthalpy. Subsequent observations suggest that this increase in diffusivity is driven by transient displacement of the enzyme's center of mass, resulting in a "recoil effect that propels the enzyme".
=== Clinical utility === A use of ion chromatography can be seen in argentation chromatography. Usually, silver and compounds containing acetylenic and ethylenic bonds have very weak interactions. This phenomenon has been widely tested on olefin compounds. The ion complexes the olefins make with silver ions are weak and made based on the overlapping of pi, sigma, and d orbitals and available electrons therefore cause no real changes in the double bond. This behavior was manipulated to separate lipids, mainly fatty acids from mixtures in to fractions with differing number of double bonds using silver ions. The ion resins were impregnated with silver ions, which were then exposed to various acids (silicic acid) to elute fatty acids of different characteristics. Detection limits as low as 1 μM can be obtained for alkali metal ions. It may be used for measurement of HbA1c, porphyrin and with water purification. Ion Exchange Resins(IER) have been widely used especially in medicines due to its high capacity and the uncomplicated system of the separation process. One of the synthetic uses is to use Ion Exchange Resins for kidney dialysis. This method is used to separate the blood elements by using the cellulose membraned artificial kidney. Another clinical application of ion chromatography is in the rapid anion exchange chromatography technique used to separate creatine kinase (CK) isoenzymes from human serum and tissue sourced in autopsy material (mostly CK rich tissues were used such as cardiac muscle and brain).
Probable migraine describes conditions that have some characteristics of migraine, but where there is not enough evidence to diagnose it as migraine with certainty. Menstrual migraines are those that either only occur associated with a menstrual period, or occur predictably around menstrual period alongside migraines during other parts of the menstrual cycle. They typically occur in migraines without aura. They are often longer than other migraine attacks, and associated with more nausea.
Sources: en.wikipedia.org
Spectrin (alpha and beta) Ankyrin Band-3 protein Protein-4.2 Lesser proteins of significance Hereditary spherocytosis can be an autosomal recessive or autosomal dominant trait. The autosomal recessive inheritance pattern accounts for close to 25% of the clinical cases. The autosomal dominant inheritance pattern accounts for over 75% of the clinical cases. Many positive individuals will not present clinically, thus the etiologic data may be artificially skewed towards the more prominent dominant forms. These dominant forms tend to leave a family history that yields generational splenectomies and black gallstones cholelithiasis. Lastly, an estimated 25% of cases are due to spontaneous mutations.
== History == The original interface between capillary zone electrophoresis and mass spectrometry was developed in 1987 by Richard D. Smith and coworkers at Pacific Northwest National Laboratory, and who also later were involved in development of interfaces with other CE variants, including capillary isotachophoresis and capillary isoelectric focusing.
=== Market Share === Tetra Pak has occasionally been subject to controversy, most notably regarding its near-monopoly position on certain markets for many years. Especially attempts at mergers have been subject to scrutiny. Its merger with French PET-production company Sidel in 2001 drew anti-competition allegations from the European Commission. The court case was drawn out for many years and twice appealed to the European Court of First Instance before the European Court of Justice ruled in favour of Tetra Laval. In 2004, Tetra Pak was accused of using its near-monopoly in China, where it owned 95 percent of the market for aseptic carton packaging. The allegations were contested by Tetra Pak.
=== Second wave (2010–2013) === The second wave of the opioid epidemic began around 2010 and is characterized by the surge in heroin use and overdose deaths. Between 2005 and 2012, the number of people who used heroin nearly doubled, growing from 380,000 to 670,000 individuals. In 2010, there were 2,789 fatal heroin overdoses, representing an almost 50% increase compared to previous years. This sharp increase can be attributed to the availability of heroin in the United States and its decreasing prices, which enticed a significant portion of individuals already dependent on opioids to switch to a more potent and cost-effective alternative. During this same period, there was a reformulation of OxyContin that made it more difficult to crush and misuse, although the precise impact of this reformulation on the rise in heroin use remains uncertain.
Sources: en.wikipedia.org
An intermediate bulk container (IBC, IBC Tote, IBC Tank) is a multi-use container employed for the general transport, storage, and handling of bulk fluids and materials. IBC tanks are compatible with, and resistant to, an extensive list of chemicals, acids, caustics, as well as inert materials and food grade consumables. IBCs are commonly manufactured from the following materials:
===== Interferon production ===== Because of powerful interferon stimulating properties, before recombinant interferon alpha became available for medical use, SeV was selected, among other viruses, for the industrial large-scale IFN production. A procedure involving inactivated SeV treatment of human peripheral blood leukocytes from donors' blood was used for this production. Below is a table that listed known PRRs and interferon regulatory factors that are getting activated upon SeV infection.
Body pain, arthralgia, myalgia Chronic fatigue and insomnia Depression, anxiety and mood disorders Gastrointestinal complications such as constipation, diarrhea, and acid reflux Weight gain or loss Frequent infections
Note: Other substances once thought to be vitamins were given B-numbers, but were disqualified once discovered to be either manufactured by the body or not essential for life. See § Related compounds for numbers 4, 8, 10, 11, and others.
Somalia is a semi-arid country with about 1.6% arable land. The first local environmental organisations were Ecoterra Somalia and the Somali Ecological Society, which promoted ecological awareness and mobilised environmental programs governmentally and through grassroots efforts. From 1971 onward, a massive tree-planting campaign on a nationwide scale was introduced by the communist government to halt the advance of wind-driven sand dunes, which threatened to engulf towns, roads and farm land. By 1988, 265 hectares of a projected 336 hectares had been treated, with 39 range reserve sites and 36 forestry plantation sites established. In 1986, the Wildlife Rescue, Research and Monitoring Centre was established by Ecoterra International, with the goal of raising ecological awareness. This effort led in 1989 to a decision by the Somali government to adhere to the Convention on International Trade in Endangered Species of Wild Fauna and Flora, which banned the trade of elephant ivory. Following the tsunami of December 2004, it was alleged that Somalia's shoreline was used to dump toxic waste. The waves after the tsunami stirred up nuclear and toxic waste that was possibly dumped illegally by foreign firms.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.